Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes
簡単な紹介:
- 著者: Junyun Lai, Cheok Weng Chan, Jesse D. Armitage, Katherine M. Audsley, Yu-Kuan Huang, Emily B. Derrick, Laura S. Carstensen, Christina M. Scheffler, Matt E. Jones, Kevin Sek, Nicola Principe, Joelle S. Kim, Imran G. House, Amanda X. Y. Chen, Kah Min Yap, Jim Middelburg, Isabelle Munoz, Dat Nguyen, Junming Tong, Thang X. Hoang, Kirsten L. Todd, Maximilien Evrard, Jonathan Chee, Laura K. Mackay, Alistair R. R. Forrest, Ian A. Parish, Anthony Bosco, Jason Waithman, Paul A. Beavis & Phillip K. Darcy
- ジャーナル: Nature Immunology
- Doi: https://www.doi.org/10.1038/s41590-026-02419-4
- 発行日: 2026/2/10
Abstract
Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation status controls response, with less differentiated cells having an enhanced capacity to proliferate after ICB. Given that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted T cells (TPEX), we hypothesized that expansion of cDC1s with Flt3L could enhance responses to ICB. Here we show that treatment with Fms-related tyrosine kinase 3 ligand (Flt3L) expands CD62L+SLAMF6+CD8+ T cells in the tumor through a mechanism that requires XCR1+ dendritic cells to traffic to the tumor-draining lymph node. The combination of Flt3L and anti-CTLA-4 enhanced therapeutic responses. Combination therapy is associated with the emergence of a CD8+ T cell subset characterized by the expression of Il21r and oligoclonal expansion of CD8+ T cells within tumors through a mechanism that is dependent on lymph node egress.
PackGeneについて
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
